Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a ...
Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data for ...
Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference SYDNEY, ...
In recent years, cancer research has undergone significant transformation, marked by the introduction of numerous innovative therapies. With the emergence of advanced PD-1/PD-L1 and CTLA-4 immune ...
Many of us have experienced jet lag after a holiday. But did you know you can have social jet lag as well? This happens when ...
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback